Main Article Content
Background. The results of a number of studies have proved the relationship between the functional state of the pineal gland and renal function. However, violations of the melatonin-forming function (MFF) of the pineal gland in patients with chronic kidney disease (CKD) undergoing hemodialysis and its relationship with the development of anemia in this population is a poorly understood issue. The purpose: to conduct a clinical assessment of anemia in patients with stage 5 CKD who are treated with hemodialysis depending on clinical and demographic parameters, and to determine its correlation with the violation of MFF. Materials and methods. We examined 130 people (50 % of men) with stage 5 CKD undergoing hemodialysis treatment. Based on the level of melatonin in saliva, patients treated with hemodialysis were divided into two groups: group I — 110 individuals with impaired MFF, group II — 20 people with normal MFF. The control group included 20 healthy individuals matched for age and gender. All patients underwent clinical and laboratory studies: general and biochemical blood tests with determination of all indicators of blood iron metabolism, lipid profile, blood pressure measurement, body mass index calculation, evaluation of the salivary melatonin concentration at different periods of the day, as well as parathyroid hormone. Results. A significant prevalence of MFF disturbance was found in patients with stage 5 CKD, which are treated with hemodialysis, and its relationship with the development of anemia. Analysis of circadian melatonin levels depending on the severity of anemia demonstrated their profound impairment in patients with moderate severity of anemia, in which a significant difference was determined by the level of melatonin at night (p = 0.004). Correlation analysis showed a weak negative correlation between the level of hemoglobin and the duration of hemodialysis (r = –0.217; p < 0.05) that may indicate the progression of anemia with an increase in the duration of renal replacement treatment. Positive correlations were established between hemoglobin concentration and the level of daytime melatonin (r = 0.193; p < 0.05), and closer relationship — with the level of nighttime melatonin (r = 0.278; p < 0.05), which reflects the correlation between the violation of MFF and hemoglobin synthesis. A negative correlation was demonstrated between ferritin and hemoglobin level (r = –0.31; p < 0.05), as well as with serum iron concentration (r = –0.202; p < 0.05) and the level of transferrin (r = –0.234; p < 0.05). A negative correlation is determined between the level of ferritin and the daytime salivary melatonin (r = –0.202; p < 0.05), and the relationship of average strength — with salivary melatonin at night (r = –0.396; p < 0.05). When analyzing the level of transferrin, we determined the positive correlation of the latter with the daytime melatonin (r = –0.332; p < 0.05), and average correlation — with melatonin level at night (r = 0.447; p < 0.05). The inverse weak correlation was found between transferrin concentration and hemodialysis duration (r = –0.191; p < 0.05). Conclusions. A high frequency of MFF disturbance was demonstrated (84.6 %), which is associated with a significant prevalence of anemia and iron deficiency in patients with stage 5 CKD undergoing hemodialysis treatment. In people receiving renal replacement treatment, a relationship was established between the degree of pineal gland dysfunction and the severity of anemia; at that, it increases with an increase in the duration of hemodialysis treatment and the duration of hypertension. In hemodialysis patients, the concentration of ferritin reflects the activity of inflammation that increases with a violation of MFF. Pineal gland dysfunction and anemia have age-dependent nature: they are most severe in old age.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94–111. doi:10.1053/j.ajkd.2004.03.023.
United States Renal Data System (USRDS). USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and EndStage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD; 2013.
Kozljuk NI, Nikolajenko SS, Razvazhajeva OO; Institute of Nephrology NAMS of Ukraine, authors; Kolesnyk MO, editor. Nacional'nyj rejestr hvoryh na hronichnu hvorobu nyrok ta pacijentiv z gostrym poshkodzhennjam nyrok: 2017 rik [National Register of Chronic Patients kidney disease and patients with acute kidney damage 2017]. Kyiv; 2018. 183 p. (in Ukrainian).
Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology (Carlton). 2005;10(6):583–587. doi:10.1111/j.1440-1797.2005.00488.x.
Kondratiuk VE, Petrova AS, Karpenko ОV. Characterization of melatonin-forming function of pineal gland in patients with end-stage chronic kidney disease. Clinical endocrinology and endocrine surgery. 2019;(68):94–102. doi:10.30978/CEES-2019-4-94. (in Ukrainian).
Hrenak J, Paulis L, Repova K, et al. Melatonin and renal protection: novel perspectives from animal experiments and human studies (review). Curr Pharm Des. 2015;21(7):936–949. doi:10.2174/1381612820666140929092929.
Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361–383. doi:10.1146/annurev-pharmtox-010814-124742.
Van der Putten K, Koch B, van Someren E, et al. The role of renal function loss on circadian misalignment of cytokines EPO, IGF-1, IL-6 and TNF-alfa in chronic renal disease. Neuro Endocrinol Lett. 2011;32(2):148–153.
Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant. 2013;28(7):1672–1679. doi:10.1093/ndt/gft021.
Likuvannja hvoryh na hronychnu hvorobu nyrok V HD stadii': adaptovana klinichna nastanova, zasnovana na dokazah, ta unifikovani klinichni protokoly [Treatment of patients with chronic kidney disease V HD stage: adapted evidence-based clinical setting and unified clinical protocols]. Kyiv: Poligraf-pljus; 2016. 228 p. (in Ukrainian).
Peng W, Lei M, Zhang J, Zhang Y. The protective effect of melatonin on the in vitro development of yak embryos against hydrogen peroxide-induced oxidative injury. Zygote. 2019;27(3):118-125. doi:10.1017/S0967199418000412.
Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014;20(2):293–307. doi:10.1093/humupd/dmt054.